Stay updated with breaking news from Co Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of...
Dublin, April 18, 2022 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country,...
/PRNewswire/ -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and...
Co-Diagnostics (NASDAQ:CODX – Get Rating) updated its first quarter 2022 earnings guidance on Thursday. The company provided earnings per share guidance of $0.170-$0.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 […]
Zacks Investment Research upgraded shares of Co-Diagnostics (NASDAQ:CODX – Get Rating) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. They currently have $7.00 price target on the stock. According to Zacks, “Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics […]